Cargando…

Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis – cross-sectional study and literature review

Abstract Rationale: Anti-CCP antibodies are detectable not only in rheumatoid arthritis (RA), but also in psoriatic arthritis (PsA). It is possible those anti-CCP antibodies are associated with features of PsA and that these auto-antibodies are useful in distinguishing PsA from RA. Objective: to eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Popescu, C, Zofotă, S, Bojincă, V, Ionescu, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973875/
https://www.ncbi.nlm.nih.gov/pubmed/24701255
_version_ 1782479385244205056
author Popescu, C
Zofotă, S
Bojincă, V
Ionescu, R
author_facet Popescu, C
Zofotă, S
Bojincă, V
Ionescu, R
author_sort Popescu, C
collection PubMed
description Abstract Rationale: Anti-CCP antibodies are detectable not only in rheumatoid arthritis (RA), but also in psoriatic arthritis (PsA). It is possible those anti-CCP antibodies are associated with features of PsA and that these auto-antibodies are useful in distinguishing PsA from RA. Objective: to evaluate the prevalence and the associations of anti-CCP antibodies in PsA patients; to evaluate the usefulness of anti-CCP antibodies in distinguishing PsA from RA. Methods and Results: The inquiry was designed as a cross-sectional study of 41 PsA patients, 139 RA patients and 147 normal subjects, which recorded demographic data, disease activity and serology: rheumatoid factor (RF), anti-CCP antibodies. Five PsA patients (12.2%) were anti-CCP positive. Compared to anti-CCP negative PsA patients, anti-CCP positive PsA patients had a more frequently a polyarticular disease pattern (p = 0.005), they were more frequently treated with biologics (p = 0.015) and less frequently with classic disease-modifying drugs (p < 0.001). An optimal positive cutoff value for anti-CCP titer was determined (11.6 U/mL), over which it is highly probable that a known PsA patient actually has RA and psoriasis. Discussion: The more aggressive the disease of anti-CCP positive PsA patients indicates the need of a more intensive management regarding anti-rheumatic treatment and follow-up. Anti-CCP antibodies can be a useful tool in differentiating PsA from RA, especially in RA-like forms of PsA, which present no elements pertaining to spondyloarthropathies. Abbreviations: anti-CCP - anti-cyclic citrullinated peptide antibodies; ACR - America College of Rheumatology; CRP - C-reactive protein; CASPAR - The Classification Criteria for Psoriatic Arthritis; DMARD – disease modifying anti-rheumatic drug; EULAR - European League against Rheumatism; ELISA - enzyme-linked immunosorbent assay; ESR - erythrocyte sedimentation rate; HLA – human leukocyte antigen; PsA - psoriatic arthritis; RA - rheumatoid arthritis; RF - rheumatoid factor; ROC - receiver operating characteristic.
format Online
Article
Text
id pubmed-3973875
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-39738752014-04-03 Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis – cross-sectional study and literature review Popescu, C Zofotă, S Bojincă, V Ionescu, R J Med Life Review Abstract Rationale: Anti-CCP antibodies are detectable not only in rheumatoid arthritis (RA), but also in psoriatic arthritis (PsA). It is possible those anti-CCP antibodies are associated with features of PsA and that these auto-antibodies are useful in distinguishing PsA from RA. Objective: to evaluate the prevalence and the associations of anti-CCP antibodies in PsA patients; to evaluate the usefulness of anti-CCP antibodies in distinguishing PsA from RA. Methods and Results: The inquiry was designed as a cross-sectional study of 41 PsA patients, 139 RA patients and 147 normal subjects, which recorded demographic data, disease activity and serology: rheumatoid factor (RF), anti-CCP antibodies. Five PsA patients (12.2%) were anti-CCP positive. Compared to anti-CCP negative PsA patients, anti-CCP positive PsA patients had a more frequently a polyarticular disease pattern (p = 0.005), they were more frequently treated with biologics (p = 0.015) and less frequently with classic disease-modifying drugs (p < 0.001). An optimal positive cutoff value for anti-CCP titer was determined (11.6 U/mL), over which it is highly probable that a known PsA patient actually has RA and psoriasis. Discussion: The more aggressive the disease of anti-CCP positive PsA patients indicates the need of a more intensive management regarding anti-rheumatic treatment and follow-up. Anti-CCP antibodies can be a useful tool in differentiating PsA from RA, especially in RA-like forms of PsA, which present no elements pertaining to spondyloarthropathies. Abbreviations: anti-CCP - anti-cyclic citrullinated peptide antibodies; ACR - America College of Rheumatology; CRP - C-reactive protein; CASPAR - The Classification Criteria for Psoriatic Arthritis; DMARD – disease modifying anti-rheumatic drug; EULAR - European League against Rheumatism; ELISA - enzyme-linked immunosorbent assay; ESR - erythrocyte sedimentation rate; HLA – human leukocyte antigen; PsA - psoriatic arthritis; RA - rheumatoid arthritis; RF - rheumatoid factor; ROC - receiver operating characteristic. Carol Davila University Press 2013-12-15 2013-12-25 /pmc/articles/PMC3973875/ /pubmed/24701255 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Popescu, C
Zofotă, S
Bojincă, V
Ionescu, R
Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis – cross-sectional study and literature review
title Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis – cross-sectional study and literature review
title_full Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis – cross-sectional study and literature review
title_fullStr Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis – cross-sectional study and literature review
title_full_unstemmed Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis – cross-sectional study and literature review
title_short Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis – cross-sectional study and literature review
title_sort anti-cyclic citrullinated peptide antibodies in psoriatic arthritis – cross-sectional study and literature review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973875/
https://www.ncbi.nlm.nih.gov/pubmed/24701255
work_keys_str_mv AT popescuc anticycliccitrullinatedpeptideantibodiesinpsoriaticarthritiscrosssectionalstudyandliteraturereview
AT zofotas anticycliccitrullinatedpeptideantibodiesinpsoriaticarthritiscrosssectionalstudyandliteraturereview
AT bojincav anticycliccitrullinatedpeptideantibodiesinpsoriaticarthritiscrosssectionalstudyandliteraturereview
AT ionescur anticycliccitrullinatedpeptideantibodiesinpsoriaticarthritiscrosssectionalstudyandliteraturereview